All In Biotech

Drug Trial Radar · NCT02724358

Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1

Last checked: Nov 20, 2026Latest source record: Mar 31, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

320

Actual

Start

Dec 2012

Primary completion

Dec 2013

Study completion Dec 2015

Sponsor

Lead sponsor
Eastern Hepatobiliary Surgery HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 31, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.

Conditions

  • Hepatocellular Carcinoma
  • TACE
  • Notch1
  • Rg3

Interventions

  • TACEProcedure

    iodized oil (5ml) + Pirarubicin (20mg)

  • Rg3Drug

    20mg, BID, maintained though Month 12.

  • TACE + Rg3Other

  • protective therapyProcedure

    standard liver protective therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: 3 years
  2. Time to progressionTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Eastern hepatobilliary surgery hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.